New infectious diseases and microorganisms continue to be described. They may be blood-or arthropod-borne, or spread by the respiratory, sexual or faecal-oral route; in some cases, modes of transmission remain unknown or new ones have been described. Complex factors have contributed to the re-emergence of older pathogens in both developing and developed countries. Changes in medical and surgical practice have led to the frequent description of resistant gram-positive and negative bacteria, fungi and bacteria.
Over the last decade there have been descriptions of new or resurgent microorganisms and infectious diseases worldwide, with the appearance of new blood-borne infections, the characterization of causative pathogens for previously recognized clinical syndromes, the re-emergence of diseases previously thought to be under control and the increase of antimicrobial-resistant organisms 1 . Many of these emerging pathogens have been first described overseas and then been brought to Australia by travellers or migrants; others have emerged locally. Although many may not necessarily be directly relevant to anaesthesia, others may be of crucial importance. There have also been recent descriptions of the transmission of infectious diseases in the context of surgery and anaesthesia where the exact mode of transmission was not determined. This includes transmission of HIV by a dentist in the U.S.A. and in a surgeon's office in Australia, and the transmission of hepatitis C following anaesthesia and surgery in Australia [2] [3] [4] .
Changes in anaesthetic practice have also introduced potential exposure to new pathogens, particularly blood-borne and respiratory ones. These changes include the increasing presence of profoundly immunosuppressed patients in hospital, more complex surgery and transplantation, and intensive care practice. Intensive care units in particular have often been the focus of nosocomial outbreaks, usually related to widespread use of broad-spectrum antibiotics and the underlying severity of illness in patients in such units.
The recognition of new syndromes, organisms or changes in antimicrobial resistance often leads to anxiety in healthcare workers and the lay public. It is therefore reasonable that anaesthetists have some knowledge of emerging pathogens, and take an interest in their description. The development of appropriate policies to cover new problems requires a balanced input from all healthcare workers. The design of infection control policies is not just the province of infectious diseases physicians, microbiologists, public health officers and bureaucrats; policies relevant to anaesthesia and surgery must have input from anaesthetists as they have the best understanding of their workplace, practices and the practicality of policy implementation in their environment.
EMERGING INFECTIOUS DISEASES
Emerging infectious diseases are defined as diseases of infectious origin where the incidence in humans has either increased within the past two decades or threatens to increase in the near future 1 . Over the last few years, a number of new infections have been described as well as a resurgence of old infections. Other organisms have developed increased resistance to available antimicrobial agents, making treatment more difficult, expensive and sometimes less effective. In the last five years or so, a number of pathogens have reached Australia for the first time, along with the first descriptions of a new human viral respiratory pathogen, unexplained transmission of HIV and hepatitis C and increasing antimicrobial resistance [3] [4] [5] .
The reason for the emergence of new infectious diseases is obviously complex and related to the interaction between the microorganism (and its vector), the host and the environment. Microorganism factors include mechanisms of genetic variability (e.g. HIV), increased virulence (e.g. development of antibiotic resistance genes by gram-positive and gram-negative bacteria), the ability to cross species barriers (e.g. HIV) and reductions in vector control or increases in insecticide resistance. Host and environment factors include expanding human populations, altered patterns of human behaviour (e.g. sexual practices, intravenous drug use), contamination of food, water and air, increased interactions with vectors and the appearance of new or altered vectors, and immunosuppression (e.g. aging, malignancy, HIV) 6 .
Newly Described Agents
In recent years a number of new blood-borne herpes viruses have been described. Human herpes virus type 6 (HHV-6, types A and B) has been associated with a number of childhood diseases, including roseola infantum and fever, and pneumonitis and encephalitis in immunocompromised hosts 7 . The association of human herpes virus type 7 (HHV-7) with human disease is less certain, but both viruses can be cultured from blood and saliva, with most people seroconverting by 2 (HHV-6) to 5 (HHV-7) years of age 8 .
Following the discovery of hepatitis C as the major cause of the non-A non-B hepatitis, new agents of hepatitis have now been described using sophisticated molecular techniques. Hepatitis G is a flavivirus distantly related to hepatitis C and is spread by blood transfusion and other parenteral routes 9 . It is associated with acute and chronic hepatitis as well as asymptomatic seropositivity and coexistence with hepatitis B or C. Other flavivirus-like agents have been implicated as causes of hepatitis in tamarin monkeys (GBV-A) and humans (GBV-B,C), but their characterization and disease association remains to be elucidated 10 . Enteric or water-borne agents of hepatitis include hepatitis E and F, with hepatitis E causing large epidemics of hepatitis in adults (with high mortality in pregnancy) in central Asia and the Indian subcontinent 11 .
Newly identified gastrointestinal pathogens include cyclospora species (associated with self-limiting diarrhoea in children and travellers to developing countries), cryptosporidia and microsporidia. In 1993 cryptosporidium was responsible for the largest outbreak of water-borne illness in the history of the United States, with over 400,000 people in Milwaukee, Wisconsin, developing diarrhoea, and over 4,000 requiring hospital admission. Cryptosporidia, microsporidia and cyclospora are all associated with prolonged diarrhoea in AIDS 12, 13 . Outbreaks of diarrhoea associated with Escherichia coli 0157:H7 and other serotypes have been associated with outbreaks of severe haemorrhagic colitis and haemolytic uraemic syndrome in the United States, South Africa, Australia and elsewhere 1 .
Two new pulmonary syndromes have been described in the last few years. An outbreak of acute respiratory disease with a mortality rate of over 50% was described in mid 1993 in the central United States, due to a newly recognized hantavirus (Sin Nombre virus) associated with rodents 14 . Other cases of similar illnesses caused by related hantaviruses have been reported elsewhere in the U.S.A., although preliminary studies have not detected human hantaviruses in Australia 15 . In 1994, an outbreak of severe respiratory disease in humans and horses due to a new paramyxovirus, the equine morbillivirus, occurred in Queensland 5 . New strains of influenza, particularly influenza A, are regularly described in both the northern and southern hemispheres with the potential for large outbreaks.
Resurgence of Old Infections
Of great concern is the re-emergence of tuberculosis (TB) in the developing and developed world. The incidence of TB has increased significantly in Africa, Asia and in large urban centres in the U.S.A., and is due to the increasing presence of AIDS, poverty and homelessness, migration and reduced funding for TB control. Associated with this have been nosocomial outbreaks of TB with disease in both patients and healthcare workers, and the isolation of multiresistant TB 16 .
The Centers for Disease Control in Atlanta, U.S.A., report a number of other re-emerging infections, including cholera in Latin America and Asia, dengue fever in central America, South East Asia and the Pacific, diphtheria in Russia, Rift Valley fever in Egypt and yellow fever in Kenya 1 . In addition to the above pathogens, other infections have emerged in conjunction with the AIDS epidemic. Examples include the fungus Penicillium marneffei (Thailand), atypical mycobacterial infections, a novel herpes virus associated with Kaposi's sarcoma and a putative HHV-8. Resistant malaria remains an issue, with some of the most resistant species seen in South East Asia and Papua New Guinea. Bartonella henselae has been identified as the causative agent for cat scratch disease and AIDS-related bacillary angiomatosis 12 .
In 1995, a dramatic outbreak of Ebola virus, a filovirus, occurred in a large town in rural Zaire, the first time since the mid 1970s that this haemorrhagic fever had occurred. Three hundred and fifteen cases occurred (including in 71 healthcare workers) with a 77% mortality rate 17 . Also described in 1995 was the laboratory acquisition by a scientist in the U.S.A. of a Brazilian arenavirus (Sabià virus), and Ebola virus by a scientist performing chimpanzee autopsies in the Côte d'Ivoire 18, 19 . Other descriptions since 1993 of related infections include Bolivian haemorrhagic fever (South America), Lassa fever (Lagos) and Congo Crimean haemorrhagic fever (UAE) 20 .
Antimicrobial Resistant Organisms
Gram-Positive Bacteria:
For many years it has been recognized that multiresistant Staphylococcus aureus (MRSA) is an important pathogen in hospitals. S.aureus has acquired genes for methicillin and gentamicin resistance. Molecular studies have demonstrated that epidemic strains spread from one hospital to another, MRSA colonization of hospital staff or patients usually precedes infection, and transmission usually occurs via the transiently colonized hands of hospital personnel. There is some regional variation in the incidence of MRSA; it is common in Australia and Europe, and is now increasing in frequency in the U.S.A. MRSA has been recognized as an important cause of nosocomial infections including septicaemia, endocarditis, osteomyelitis and postoperative wound infections, with a predisposition for medical devices such as intravenous lines and orthopaedic prosthetic devices 21, 22 . Multi-resistant S.epidermidis (MRSE) and other coagulase negative staphylococci are also important nosocomial pathogens. MRSA and MRSE are usually resistant to all β-lactam antibiotics, and vancomycin is the treatment of choice. The potential for developing vancomycin resistance is present in staphylococci; however, clinically significant vancomycin resistant isolates are fortunately rare. Multiresistant staphylococci are variably resistant to the oral agents ciprofloxacin, rifampicin and fusidic acid.
Enterococci are commonly isolated in hospitals, particularly from the gastrointestinal system. Although previously not often thought to be clinically significant, they are emerging as important noso-comial pathogens. They are inherently resistant to many antibiotics including the penicillins, cephalosporins and aminoglycosides, and have now acquired resistance to a wide range of other agents. This leaves vancomycin as the main treatment option; however, in recent years there has been an increase in the development of vancomycin resistance, initially in France and the U.S.A. Enterococcal resistance to vancomycin is plasmid-mediated, leading to the possibility of transfer of this plasmid to other Grampositive organisms including staphylococci 23 .
Streptococcus pneumoniae is an important cause of community acquired pneumonia, meningitis and septicaemia. Various types of penicillin resistance are described, with increasing circulation of pneumococci with intermediate resistance to penicillin (MIC <1 mg/litre) and high level resistance (MIC >1 mg/litre). Pneumococci with intermediate penicillin resistance have a decreased susceptibility to all β-lactam antibiotics including the third generation cephalosporins, as well as to the new carbapenems (imipenem) 21, 24 .
Gram-Negative Bacteria:
Gram-negative organisms, particularly the enterobacteriaceae and pseudomonas species, have long been recognized as important nosocomial pathogens, usually in intensive care units. Although many mechanisms of resistance have been shown for various members of the enterobacteriaceae, the first important one was the production of β-lactamases by E.coli via the TEM-1 plasmid. This led to widespread E.coli resistance to amoxycillin, followed by resistance to the first and second generation cephalosporins. It is also recognized that many enterobacteriaceae have a chromosomally mediated β-lactamases conferring resistance to cephalosporins. Normally these genes are repressed and then induced in the presence of a β-lactam antibiotic. Mutations have led to a stable derepression of this chromosome leading to Enterobacter cloacae, klebsiella species and other enterobacteriaceae permanently resistant to these agents. Changes in the TEM plasmid mediated β-lactamases has led to increasing resistance to the third generation cephalosporins; these extended spectrum β-lactamases (ESBL) have been a feature of klebsiella species. More plasmids (including the TEM and SHV plasmids of K.pneumoniae) have now been associated with ESBL organisms and their presence means that even the newer fourth generation cephalosporins are likely to rapidly become ineffective. Compounds that inhibit mainly the TEM and SHV β-lactamases have been developed (clavulanic acid, sulbactam and tazobactam) and combined with a number of antibiotics. However, TEM plasmid mediated β-lactamases have developed that are also resistant to these inhibitors, particularly in E.coli. 21, 25 .
Pseudomonas aeruginosa is a major nosocomial problem with its antibiotic resistance mainly due to its ability to restrict the uptake of antibiotics through porin channels in the cell wall. Drugs like ceftazidime, ticarcillin-clavulanic acid, quinolones and imipenem have been used in the treatment of severe hospital-acquired pseudomonas infections, but given the ability of pseudomonas to develop resistance, it will remain an important hospital pathogen. The widespread use of quinolone and carbapenem antibiotics has allowed the increase in other nosocomial pathogens such as acinetobacter and xanthomonas (now called sternotrophomonas) species 21 .
Fungi:
Resistance has been described in fungi following the widespread use of fluconazole and other azole antifungal agents. Resistant candida species have been described in patients on prophylaxis or therapy for oropharyngeal candidiasis in AIDS and other forms of immunosuppression leading to clinical therapeutic failures. Other fungi (e.g. fusarium and pseudoallescheria) intrinsically resistant to current anti-fungal agents have been noted, sometimes in association with intravenous lines 26 .
Viruses:
Laboratory and clinical resistance to antivirals occurs rapidly with HIV, and transmission of resistant HIV from mother to child and between sexual partners has been described 27 . Acyclovir-resistant herpes simplex and varicella zoster viruses occur, usually in the context of severe mucocutaneous lesions in immunosuppressed patients. Cytomegalovirus resistance to ganciclovir and foscarnet is also relatively common in AIDS and transplantation, with occasional patient-to-patient transmission 28 .
Emerging Pathogens in Australia
Over the last five years, a number of pathogens found elsewhere have now been described in Australia, some of which may impinge on anaesthetic practice (Table 1) . New blood-borne viruses identified in Australia include the human T cell leukaemia virus types 1 and 2 (HTLV-1,2) and HIV-2; blood supplies are now routinely screened for these viruses [29] [30] [31] . HTLV-2 is uncommon, but HTLV-1 is present in both Caucasian and Aboriginal populations and associated with neurological disorders and T cell leukaemias. HIV-1 has been present in Australia for well over ten years, although recent work has shown that newer subtypes of HIV-1 from South East Asia are detected locally 32 . Long-and short-term survivors with HIV infection have been described in Sydney (possibly related to HIV strains with altered virulence) as have uncommon modes of transmission, e.g. in a surgeon's rooms and via breast milk and artificial insemination 3, [33] [34] [35] . At the time of writing there have been five cases of occupationally acquired HIV-1 in Australia 36 . AIDS patients in Australia have been associated with antiviral resistant cytomegalovirus, herpes simplex and varicella zoster virus infections and transmission of AZT resistant virus. The second human immunodeficiency virus, HIV-2, has been detected in a number of immigrants to Australia from HIV-2 endemic areas in West Africa 31 . Hepatitis G has been detected in Australia, but formal studies on the new hepatitis viruses are pending 10 .
A number of non blood-borne viral infections have either emerged or increased in the last few years. Japanese B encephalitis, a virus similar to Australian (previously Murray Valley) encephalitis has now been detected in the Torres Strait Islands and Northern Queensland 37 . There have been recent outbreaks of other arbovirus infections, including Barmah Forest virus in southwestern Australia, the Northern Territory and southeastern N.S.W., and dengue fever in the Townsville area of Queensland 38, 39 . There is a 187 ANAESTHESIA AND EMERGING INFECTIOUS DISEASES Anaesthesia and Intensive Care, Vol. 24, No. 2, April 1996 wide range of other Australian arboviruses that are either epidemic or endemic in certain parts of the country, including flaviviruses (Australian encephalitis, Kunjin, Kokobera etc.) and alphaviruses (Barmah Forest, Ross River, Getah etc.). Hepatitis E has been diagnosed in travellers returning from endemic areas and indigenous hepatitis E has been reported from the Northern Territory 40 . There has also been the description of a new agent, the equine morbillivirus, causing a fatal pneumonitis in horses and humans in southeastern Queensland 5 . Although the diagnoses of viral haemorrhagic fevers have not been confirmed in Australia, it is estimated that one traveller per ten years could return to N.S.W. incubating such an illness 41 . Widespread antibiotic use in Australian hospitals has led to similar descriptions of antibiotic resistance in common bacteria as seen overseas. These include MRSA, MRSE, vancomycin-resistant enterococci, intermediate and high level penicillin-resistant pneumococci, extended spectrum β-lactamase producing klebsiella, and resistant pseudomonas and acinetobacter species. In eastern Australia, approximately 30% of S. aureus isolates are MRSA. MRSA is rare in Western Australia although local (the so-called "Kimberley" strain) isolates with methicillin resistance but sensitivity to other antibiotics including gentamicin are circulating 42 . National surveillance programs, involving intensive care units and microbiology laboratories, have been set up to monitor the prevalence and spread of these organisms.
Multi-resistant TB occurs occasionally and has been associated with clinical disease: these are usually imported by people from endemic areas. Other recently described infections include tick typhus along the eastern seaboard of Australia (including in the Sydney metropolitan area), potential Lyme disease and brucellosis related to feral pig hunting in Queensland 43, 44 . Outbreaks of common childhood illnesses (e.g. measles, pertussis, Haemophilus influenzae type B) related to poor vaccine uptake in the community occur regularly.
INFECTIOUS DISEASES RISK REDUCTION BY ANAESTHETISTS
Many of the emerging pathogens described above will have limited impact on routine anaesthetic practice, but some (particularly blood-borne or respiratory ones) will be important. There are a number of ways that anaesthetists and other healthcare workers can protect themselves against potential problems ( Table 2 ). It is reasonable that medical officers have some knowledge of emerging pathogens, both locally and globally, and that they understand their workplace risks and explain these to allied staff. Obviously the type of anaesthetic practice is important-for example paediatric, obstetric, cardiac and adult anaesthesia all have specific exposure problems. Examination of workplace practices needs to be ongoing as new infection problems will continue to occur as exemplified by recent descriptions of contaminated lipid-based anaesthetic drugs associated with postoperative infections, HIV persistance in multidose anaesthetic vials, proper sharps disposal reduction of needlestick injuries, and HIV and Creutzfeld-Jakob disease transmission by human tissue [45] [46] [47] . It should also be remembered that anaesthesia and surgery are immunosuppressive procedures for patients; this may be important in reactivation of TB or herpes viruses, wound healing, etc.
The key to combating any new pathogen is the selection, implementation and practice of appropriate infection control guidelines. The concept of universal precautions, where all patients are regarded as being potentially infectious, has been in place for over five years 48, 49 . It is crucial that anaesthetists understand this concept and are prepared to follow it at all times in the workplace. For infection control policies to be effective, it is appropriate that anaesthetists have a role in their implementation in the workplace. Any needlestick or other body fluid exposures should be reported by all staff and confi-188 D. E. DWYER Anaesthesia and Intensive Care, Vol. 24, No. 2, April 1996 It is reasonable to expect anaesthetists to ask their patients basic questions in the preoperative assessment concerning potential underlying infections or their risk factors. Discussion of risk factors is important as blood-borne viruses such as HIV, hepatitis C or B, and HTLV are infectious even in the presence of often longstanding asymptomatic or unrecognized illness. However, it must be remembered that the absence of identifiable (or admitted) risk factors in no way excludes the presence of disease.
Given that many emerging pathogens described above have entered Australia via travellers or migrants, a brief travel history (with translator assistance if required) is appropriate. This includes both migration and recent travel, although what to do with a patient in the preoperative situation who gives such a history is problematic. Apart from the chest X-ray and routine blood tests, there are no simple screening tests for patients incubating exotic illnesses. If suspicion has been aroused, then expert advice needs to be obtained for appropriate investigation. Decisions made on whether surgery should be delayed or empiric therapy commenced will need to be made depending on the clinical state of the patient and remembering that investigation of rare pathogens may not always be rapid.
Those anaesthetists with influence on antibiotic prescribing, particularly in intensive care units or in surgical and cardiac valve prophylaxis, should have some knowledge of antimicrobial agents and the pattern of antimicrobial resistance in their own unit or hospital. Basic knowledge about antibiotic indications is reasonable, particularly related to wound, respiratory, nosocomial and intravenous line associated infections. If in doubt, expert advice should be sought.
All healthcare workers should take responsibility for their own personal health. Hepatitis B vaccination rates have not always been ideal in healthcare workers, although the situation is improving. Other vaccinations may be appropriate. There are also recommendations for healthcare workers involved in exposure-prone procedures to self-test for thepresence of blood-borne pathogens, particularly hepatitis B, hepatitis C and HIV and workplace recommendations for healthcare workers infected with one of these viruses 51 . The issue of screening all patients (or healthcare workers) for HIV, hepatitis and other blood-borne pathogens is complex, but adherence to current infection control procedures and a reasonable index of suspicion provides the main protection for patients and staff. For anaesthetists whose practice includes travel, sports medicine, trauma, animal research, service in the armed forces or disaster-relief teams etc., specialized advice about vaccinations and protection against pathogens will be required. The Commonwealth Department of Human Services and Health publishes a fortnightly bulletin, "Communicable Diseases Intelligence", containing infectious diseases surveillance data, and overseas and local updates on infectious diseases.
CONCLUSION
Over the last five years, a number of new pathogens and infections have been described around the world and in Australia. Given the factors that contribute to such pathogens, it is highly likely that we will continue to see the emergence of these problems, some of which may be directly relevant to healthcare workers in Australia. With the advent of improved diagnostic procedures, particularly molecular techniques, it is likely that new pathogens responsible for clinical syndromes will continue to be elucidated. The battle between microorganisms and antimicrobial agents will continue, and antimicrobial resistance will only worsen. It is therefore important that anaesthetists be aware of the descriptions of new diseases and drugs, and participate in measures designed to minimize disease transmission to patients and staff.
